Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

170 recalls · Class III, newest first

Class III · Low risk

Cetirizine Hydrochloride Syrup

Failed impurities/degradation specifications; out of specification for the known impurity 4-chlorobenzophenone.

Terminated Impurity / degradation Qualitest Pharmaceuticals NDC 0603-9063-54 D-394-2014
Class III · Low risk

Folic Acid Injection

Failed Impurities/Degradation specifications: out-of-specification results 14 & 15 month time point

Terminated Impurity / degradation Fresenius Kabi USA, LLC NDC 63323-184-11 D-379-2014
Class III · Low risk

Qnasl (beclomethasone dipropionate)

Defective Delivery System: There is a potential for some units in certain lots of Qnasl Nasal Aerosol 80 mcg metered spray to have clogged stem valves.

Terminated Packaging defect Teva Pharmaceuticals USA NDC 59310-210-12 D-382-2014
Class III · Low risk

Ketoconazole Cream

Failed Impurities/Degradation Specifications: Out-of-Specification degradant results.

Terminated Impurity / degradation Fougera Pharmaceuticals Inc. NDC 0168-0099-30 D-1044-2014
Class III · Low risk

Namenda XR

Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.

Terminated Dissolution failure Forest Pharmaceuticals Inc NDC 0456-3428-05 D-1065-2014
Class III · Low risk

Namenda XR

Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.

Terminated Dissolution failure Forest Pharmaceuticals Inc NDC 0456-3400-29 D-1064-2014
Class III · Low risk

Namenda XR

Failed Dissolution Specifications: Three lots of product being recalled having failed stability dissolution testing.

Terminated Dissolution failure Forest Pharmaceuticals Inc NDC 0456-3407-33 D-1063-2014
Class III · Low risk

Paclitaxel Injection

Labeling: Incorrect or Missing Package Insert- Missing text on the product insert in the "Clinical Studies" and "Specific Adverse Events" sections.

Terminated Labeling / mix-up Fresenius Kabi USA, LLC NDC 63323-763-50 D-016-2014
Class III · Low risk

Bumetanide Tablets USP 0.5 mg. Rx Only

Failed Moisture Limit; Out of Specification (OOS) results were obtained for moisture content during stability testing at the 12 month time point, controlled room temperature conditions.

Terminated Temperature excursion Sandoz Inc D-341-2014
Class III · Low risk

Glipizide XL

Failed Dissolution Specification; the bulk lot yielded an out of specification result at the 8 hr timepoint, 18 month interval

Terminated Dissolution failure Greenstone Llc NDC 59762-5032-2 D-1059-2014
Class III · Low risk

Glucotrol XL

Failed Dissolution Specification; 8 hr stability timepoint

Terminated Dissolution failure Pfizer Inc. NDC 0049-1550-66 D-1058-2014
Class III · Low risk

Acyclovir Oral Suspension

Failed Stability Specification; product viscosity and or pH are below specification.

Terminated Stability / shelf life Hi-Tech Pharmacal Co., Inc. NDC 50383-810-16 D-389-2014
Class III · Low risk

Potassium Chloride

Labeling: Incorrect or Missing Package Insert: the package insert for the potassium chloride 8 mEq and 10 mEq strength instead of the potassium chloride 10 mEq and 20 mEq strength was packaged with the product.

Terminated Labeling / mix-up Cardinal Health D-0489-2015
Class III · Low risk

Hydroxychloroquine Sulfate Tablets

Failed Tablet/Capsule Specifications: Sandoz is recalling one lot of Hydroxychloroquine Sulfate Tablets, USP, 200mg, due to illegibility of the logo on some tablets.

Terminated Failed specification Sandoz Incorporated NDC 0781-1407-01 D-66373-001
Class III · Low risk

Acanya (Clindamycin Phosphate and Benzoyl Peroxide)

Labeling: Incorrect or Missing Lot and/or Exp Date: This recall is being carried out due to an incorrect expiration date assigned to a lot of physicians samples.

Terminated Labeling / mix-up Valeant Pharmaceuticals North Am NDC 13548-132-03 D-020-2014
Class III · Low risk

Endometrin

Discoloration; due to prolonged heat exposure.

Terminated Failed specification Ferring Pharmaceuticals Inc NDC 55566-6500-3 D-1426-2014
Class III · Low risk

Venlafaxine

Failed Dissolution Specification:12 hour time point at 18 months of product shelf life.

Terminated Dissolution failure Osmotica Pharmaceutical Corp NDC 0131-3268-32 D-1067-2013
Class III · Low risk

Loratadine 24 HR-OTC

Failed Tablet/Capsule Specifications: Affected lot numbers may contain chipped or broken tablets.

Terminated Failed specification Physicians Total Care, Inc. NDC 54868-5268-00 D-0239-2015
Class III · Low risk

Timolol Maleate Sterile Ophthalmic Solution

Defective Container: Stability samples of both products were noted to have some white solid product residue, identified as dried active ingredients along with the preservative, on the exterior of the bottles.

Terminated Packaging defect PACK Pharmaceuticals, LLC NDC 16571-141-10 D-1073-2014

Recalls by year